Does the media refer more to SMMT or IOVA?

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.95 beat Iovance Biotherapeutics' score of 0.44 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer IOVA or KYMR?

In the previous week, Iovance Biotherapeutics had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 3 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.87 beat Iovance Biotherapeutics' score of 0.44 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or IOVA?

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 11 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.44 beat Halozyme Therapeutics' score of 0.24 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IOVA or SYRE?

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.57 beat Iovance Biotherapeutics' score of 0.44 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Iovance Biotherapeutics (IOVA) Competitors

$7.76 +0.13 (+1.70%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$7.74 -0.01 (-0.19%)

As of 11/13/2026 07:58 PM Eastern

Compare

IOVA vs. SMMT, KYMR, HALO, BMRN, and SYRE

Should you buy Iovance Biotherapeutics stock or one of its competitors? Iovance Biotherapeutics's main competitors and comparable companies include Summit Therapeutics (SMMT), Kymera Therapeutics (KYMR), Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Iovance Biotherapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Summit Therapeutics has a beta of -1.49, indicating that its share price is 249% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 81.8% of Summit Therapeutics shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summit Therapeutics currently has a consensus target price of $28.61, suggesting a potential upside of 102.17%. Iovance Biotherapeutics has a consensus target price of $13.80, suggesting a potential upside of 77.84%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.95 beat Iovance Biotherapeutics' score of 0.44 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summit Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -58.20%. Iovance Biotherapeutics' return on equity of -29.71% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-138.82%	-117.11%
Iovance Biotherapeutics	-58.20%	-29.71%	-23.55%

Iovance Biotherapeutics has higher revenue and earnings than Summit Therapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.07	N/A
Iovance Biotherapeutics	$378.98M	9.47	-$390.98M	-$0.53	N/A

Summary

Iovance Biotherapeutics beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Iovance Biotherapeutics had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 3 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.87 beat Iovance Biotherapeutics' score of 0.44 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Iovance Biotherapeutics currently has a consensus target price of $13.80, suggesting a potential upside of 77.84%. Kymera Therapeutics has a consensus target price of $139.16, suggesting a potential upside of 9.09%. Given Iovance Biotherapeutics' higher possible upside, research analysts plainly believe Iovance Biotherapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.89

Iovance Biotherapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Kymera Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$378.98M	9.47	-$390.98M	-$0.53	N/A
Kymera Therapeutics	$39.21M	277.75	-$311.35M	-$3.62	N/A

Iovance Biotherapeutics has a net margin of -58.20% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -22.39% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-58.20%	-29.71%	-23.55%
Kymera Therapeutics	-285.33%	-22.39%	-20.48%

Summary

Kymera Therapeutics beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 11 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.44 beat Halozyme Therapeutics' score of 0.24 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Halozyme Therapeutics presently has a consensus target price of $108.18, indicating a potential upside of 7.89%. Iovance Biotherapeutics has a consensus target price of $13.80, indicating a potential upside of 77.84%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Halozyme Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.19	$316.89M	$3.93	25.51
Iovance Biotherapeutics	$378.98M	9.47	-$390.98M	-$0.53	N/A

Halozyme Therapeutics has a net margin of 26.93% compared to Iovance Biotherapeutics' net margin of -58.20%. Halozyme Therapeutics' return on equity of 751.81% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	26.93%	751.81%	23.84%
Iovance Biotherapeutics	-58.20%	-29.71%	-23.55%

Summary

Halozyme Therapeutics beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 2 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 10 mentions for BioMarin Pharmaceutical. Iovance Biotherapeutics' average media sentiment score of 0.44 beat BioMarin Pharmaceutical's score of 0.30 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has a net margin of -0.52% compared to Iovance Biotherapeutics' net margin of -58.20%. BioMarin Pharmaceutical's return on equity of 5.58% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	-0.52%	5.58%	3.51%
Iovance Biotherapeutics	-58.20%	-29.71%	-23.55%

BioMarin Pharmaceutical has higher revenue and earnings than Iovance Biotherapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.44	$348.90M	-$0.10	N/A
Iovance Biotherapeutics	$378.98M	9.47	-$390.98M	-$0.53	N/A

BioMarin Pharmaceutical has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

BioMarin Pharmaceutical presently has a consensus price target of $87.22, suggesting a potential upside of 52.40%. Iovance Biotherapeutics has a consensus price target of $13.80, suggesting a potential upside of 77.84%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.80
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

BioMarin Pharmaceutical beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Spyre Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Iovance Biotherapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.24, indicating that its share price is 224% more volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spyre Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$378.98M	9.47	-$390.98M	-$0.53	N/A
Spyre Therapeutics	$890K	11,097.62	-$155.20M	-$2.74	N/A

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.57 beat Iovance Biotherapeutics' score of 0.44 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics presently has a consensus target price of $13.80, suggesting a potential upside of 77.84%. Spyre Therapeutics has a consensus target price of $110.53, suggesting a potential upside of 6.28%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Spyre Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -58.20%. Iovance Biotherapeutics' return on equity of -29.71% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-58.20%	-29.71%	-23.55%
Spyre Therapeutics	N/A	-35.97%	-27.67%

Summary

Spyre Therapeutics beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.53B	$4.12B	$7.84B	$12.19B
Dividend Yield	N/A	3.62%	2.46%	4.53%
P/E Ratio	-14.64	25.73	34.71	28.44
Price / Sales	9.47	16.57	8.66	5.84
Price / Cash	N/A	26.37	21.93	22.49
Price / Book	4.41	4.00	4.35	3.76
Net Income	-$390.98M	-$22.78M	$3.51B	$390.55M
7 Day Performance	-3.48%	-2.85%	-1.49%	-0.33%
1 Month Performance	-45.39%	-3.75%	-2.55%	-4.82%
1 Year Performance	214.17%	-1.56%	0.92%	-5.83%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	2.7129 of 5 stars	$7.76 +1.7%	$13.80 +77.8%	+222.0%	$3.53B	$378.98M	N/A	975	Gap Up
SMMT Summit Therapeutics	3.0799 of 5 stars	$17.84 +9.2%	$28.61 +60.4%	-22.5%	$14.27B	N/A	N/A	265
KYMR Kymera Therapeutics	1.9827 of 5 stars	$138.86 +5.4%	$139.16 +0.2%	+100.5%	$11.85B	$102.24M	N/A	285
HALO Halozyme Therapeutics	3.9767 of 5 stars	$102.92 -0.7%	$106.73 +3.7%	+40.8%	$11.73B	$1.40B	26.19	423	Analyst Downgrade
BMRN BioMarin Pharmaceutical	4.2161 of 5 stars	$57.18 +2.1%	$87.91 +53.7%	+5.6%	$11.08B	$3.22B	N/A	3,221	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. SMMT, KYMR, HALO, BMRN, and SYRE

How does Iovance Biotherapeutics compare to Summit Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Summary

How does Iovance Biotherapeutics compare to BioMarin Pharmaceutical?

Summary

How does Iovance Biotherapeutics compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. SMMT, KYMR, HALO, BMRN, and SYRE

How does Iovance Biotherapeutics compare to Summit Therapeutics?

Which has more volatility and risk, SMMT or IOVA?

Do insiders and institutionals hold more shares of SMMT or IOVA?

Do analysts rate SMMT or IOVA?

Does the media refer more to SMMT or IOVA?

Is SMMT or IOVA more profitable?

Which has higher valuation & earnings, SMMT or IOVA?

Summary

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Does the media prefer IOVA or KYMR?

Do insiders and institutionals have more ownership in IOVA or KYMR?

Do analysts prefer IOVA or KYMR?

Which has more risk & volatility, IOVA or KYMR?

Which has better earnings & valuation, IOVA or KYMR?

Is IOVA or KYMR more profitable?

Summary

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Do insiders & institutionals believe in HALO or IOVA?

Does the media prefer HALO or IOVA?

Do analysts rate HALO or IOVA?

Which has more volatility & risk, HALO or IOVA?

Which has preferable valuation and earnings, HALO or IOVA?

Is HALO or IOVA more profitable?

Summary

How does Iovance Biotherapeutics compare to BioMarin Pharmaceutical?

Do insiders & institutionals hold more shares of BMRN or IOVA?

Does the media refer more to BMRN or IOVA?

Is BMRN or IOVA more profitable?

Which has preferable earnings and valuation, BMRN or IOVA?

Which has more risk & volatility, BMRN or IOVA?

Do analysts rate BMRN or IOVA?

Summary

How does Iovance Biotherapeutics compare to Spyre Therapeutics?

Which has more volatility and risk, IOVA or SYRE?

Do institutionals and insiders have more ownership in IOVA or SYRE?

Which has stronger valuation and earnings, IOVA or SYRE?

Does the media favor IOVA or SYRE?

Do analysts prefer IOVA or SYRE?

Is IOVA or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools